ProShares Ultra NASDAQ Biotechnology
28 hedge funds and large institutions have $23.7M invested in ProShares Ultra NASDAQ Biotechnology in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 9 closing their positions.
20% more capital invested
Capital invested by funds: $19.8M → $23.7M (+$3.92M)
1.23% more ownership
Funds ownership: 4.88% → 6.11% (+1.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 31 → 28 (-3)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
48% less call options, than puts
Call options by funds: $5.84M | Put options by funds: $11.2M
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIAN
Mariner Independent Advisor Network
Overland Park,
Kansas
|
+$3.9M |
| 2 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
+$1.88M |
| 3 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$1.02M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$427K |
| 5 |
Walleye Trading
New York
|
+$149K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
-$1.32M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$818K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$685K |
| 4 |
RIA
RPG Investment Advisory
Pleasanton,
California
|
-$624K |
| 5 |
Jane Street
New York
|
-$484K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CG
26
Cutler Group
San Francisco,
California
| $4K | +$4.65K | +100 | New |
|
|
27
Walleye Trading
New York
| $171 | +$149K | +3,204 | +956% |
|
|
BG
28
Bellevue Group
Kuesnacht,
Switzerland
| – | -$818K | -20,500 | Closed |
|
|
VKH
29
Virtu KCG Holdings
New York
| – | -$466K | -11,672 | Closed |
|
|
30
Jane Street
New York
| – | -$484K | -10,417 | Closed |
|
|
HF
31
HRT Financial
New York
| – | -$413K | -10,360 | Closed |
|
32
Wolverine Trading
Chicago,
Illinois
| – | -$274K | -6,874 | Closed |
|
|
BPC
33
Banque Pictet & Cie
Geneva 73,
Switzerland
| – | -$239K | -6,000 | Closed |
|
|
VF
34
Virtu Financial
New York
| – | -$213K | -5,341 | Closed |
|
35
Simplex Trading
Chicago,
Illinois
| – | -$96K | -2,429 | Closed |
|
|
EWM
36
Edge Wealth Management
New York
| – | -$20K | -500 | Closed |
|
BIB Hedge Fund Activity: Q1 2017 in Review
28 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2017, worth a combined $23.7M — up 20% from $19.8M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of BIB and 7 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 3 added.
The largest buyer was Mariner Independent Advisor Network, opening a new position worth an estimated $3.9M. The largest seller was Creative Planning, cutting an estimated $1.32M.
- 28 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2017, down from 31 in Q4 2016.
- Funds reported $23.7M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2017, up 20% quarter-over-quarter.
- 7 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2017 and 9 closed out, a net change of -2 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2017 was Mariner Independent Advisor Network, an estimated $3.9M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2017 was Creative Planning, an estimated $1.32M sold.
Based on aggregated 13F filings for Q1 2017.